Skip to main content
. 2021 Aug 26;148(8):2137–2144. doi: 10.1007/s00432-021-03774-5

Fig. 5.

Fig. 5

Progression free survival (PFS) under the therapeutic regimen directly preceding the molecular therapies (left) versus PFS under the molecularly targeted therapy (right). Colors indicating the response at 3 months follow-up